These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17693000)

  • 1. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE).
    Pugachev KV; Schwaiger J; Brown N; Zhang ZX; Catalan J; Mitchell FS; Ocran SW; Rumyantsev AA; Khromykh AA; Monath TP; Guirakhoo F
    Vaccine; 2007 Sep; 25(37-38):6661-71. PubMed ID: 17693000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
    Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
    Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys.
    Monath TP; Myers GA; Beck RA; Knauber M; Scappaticci K; Pullano T; Archambault WT; Catalan J; Miller C; Zhang ZX; Shin S; Pugachev K; Draper K; Levenbook IS; Guirakhoo F
    Biologicals; 2005 Sep; 33(3):131-44. PubMed ID: 15975826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.
    Brandler S; Brown N; Ermak TH; Mitchell F; Parsons M; Zhang Z; Lang J; Monath TP; Guirakhoo F
    Am J Trop Med Hyg; 2005 Jan; 72(1):74-81. PubMed ID: 15728870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
    Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
    Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice.
    Liu WJ; Wang XJ; Clark DC; Lobigs M; Hall RA; Khromykh AA
    J Virol; 2006 Mar; 80(5):2396-404. PubMed ID: 16474146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
    Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
    J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
    Arroyo J; Guirakhoo F; Fenner S; Zhang ZX; Monath TP; Chambers TJ
    J Virol; 2001 Jan; 75(2):934-42. PubMed ID: 11134306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.
    Monath TP; Arroyo J; Levenbook I; Zhang ZX; Catalan J; Draper K; Guirakhoo F
    J Virol; 2002 Feb; 76(4):1932-43. PubMed ID: 11799188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.
    Lai CJ; Monath TP
    Adv Virus Res; 2003; 61():469-509. PubMed ID: 14714441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.
    Long MT; Gibbs EP; Mellencamp MW; Zhang S; Barnett DC; Seino KK; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):486-90. PubMed ID: 18065304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus.
    Maier CC; Delagrave S; Zhang ZX; Brown N; Monath TP; Pugachev KV; Guirakhoo F
    Virology; 2007 Jun; 362(2):468-74. PubMed ID: 17303204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3' deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice.
    Pletnev AG
    Virology; 2001 Apr; 282(2):288-300. PubMed ID: 11289811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.
    Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
    Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
    J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.
    Monath TP; McCarthy K; Bedford P; Johnson CT; Nichols R; Yoksan S; Marchesani R; Knauber M; Wells KH; Arroyo J; Guirakhoo F
    Vaccine; 2002 Jan; 20(7-8):1004-18. PubMed ID: 11803060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.